 WESTLAKE VILLAGE, Calif., Sept. 09, 2021 GLOBE NEWSWIRE -- Arcutis Biotherapeutics, Inc. Nasdaq: ARQT, a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, today announced that Arcutis management will participate in two upcoming investor conferences in September. 